A Validated UHPLC–MS/MS Method to Quantify Eight Antibiotics in Quantitative Dried Blood Spots in Support of Pharmacokinetic Studies in Neonates

Objectives: Conduction of pharmacokinetic (PK) study in pediatric patients is challenging due to blood sampling limits. The dried blood spots (DBS) method represents a potential matrix for microsampling in support of PK studies in children. Herein, we used the Capitainer® qDBS device to develop a DBS method that can collect an exact 10 µL volume of blood on a paper card. This DBS method was developed to simultaneously quantify the concentrations of eight antibiotics, including sulbactam, tazobactam, ampicillin, meropenem, cefotaxime, cefoperazone, piperacillin, and metronidazole using ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS). Methods: The prepared DBS samples were extracted in methanol containing acetaminophen as the internal standard at 20 °C on a block bath shaker at 500 rpm for 30 min. The extracted antibiotics were eluted on an Acquity UPLC HSS T3 column (2.1 × 50 mm, 1.8 µm) using gradient elution with a total chromatographic run time of 6.5 min. The precursor and product ions of the analytes were detected by use of the multiple reaction monitoring (MRM) mode. Results: No interfering peaks at the respective retention times of the analytes were observed in DBS samples. The lower limits of quantification (LLOQ) for the antibiotics were between 0.25 and 2.0 μg/mL, and satisfactory accuracies (intra/inter-assay bias −16.7 to +13.6%) and precisions (intra/inter-assay coefficient of variations 1.5–15.6%) were obtained for the analytes. As a proof of concept, the method was applied to DBS samples obtained from neonatal patients treated with ampicillin and piperacillin/sulbactam. Conclusions: The DBS method is simple and robust, and it can be used in children with limited blood sampling.

[1]  S. Bode-Böger,et al.  Quantification of ceftazidime/avibactam in human plasma and dried blood spots: Implications on stability and sample transport. , 2022, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[2]  Sanwang Li,et al.  An UPLC-PDA assay for simultaneous determination of seven antibiotics in human plasma. , 2021, Journal of pharmaceutical and biomedical analysis.

[3]  R. Linden,et al.  Development and validation of an assay for the measurement of gentamicin concentrations in dried blood spots using UHPLC-MS/MS. , 2021, Journal of pharmaceutical and biomedical analysis.

[4]  S. Mallayasamy,et al.  Validation of an HPLC method for estimation of cefotaxime from dried blood spot: alternative to plasma-based PK evaluation in neonates. , 2021, Bioanalysis.

[5]  C. R. Stensvold,et al.  Impact of Metronidazole Treatment and Dientamoeba Fragilis Colonization on Gut Microbiota Diversity , 2021, Journal of pediatric gastroenterology and nutrition.

[6]  K. Sridharan,et al.  Off-label drug use and the risk of medication errors in critically ill neonates: A conceptual pilot study. , 2021, The International journal of risk & safety in medicine.

[7]  M. Sharland,et al.  Variation in Target Attainment of Beta‐Lactam Antibiotic Dosing Between International Pediatric Formularies , 2021, Clinical pharmacology and therapeutics.

[8]  Christophe Stove,et al.  Alternative Sampling Devices to Collect Dried Blood Microsamples: State-of-the-Art , 2021, Therapeutic drug monitoring.

[9]  S. Robinson,et al.  Little to Give, Much to Gain—What Can You Do With a Dried Blood Spot? , 2020, Current Environmental Health Reports.

[10]  Jinson J. Erinjeri,et al.  Safety of Metronidazole in Late Pre-term and Term Infants with Complicated Intra-abdominal Infections , 2020, The Pediatric infectious disease journal.

[11]  U. Tröger,et al.  Stability of meropenem in plasma versus dried blood spots (DBS) , 2019, Journal of pharmaceutical and biomedical analysis.

[12]  C. Stove,et al.  Is the hematocrit still an issue in quantitative dried blood spot analysis? , 2019, Journal of pharmaceutical and biomedical analysis.

[13]  G. Kearns,et al.  Developmental Changes in Pharmacokinetics and Pharmacodynamics , 2018, Journal of clinical pharmacology.

[14]  M. Breadmore,et al.  Precise, accurate and user-independent blood collection system for dried blood spot sample preparation , 2018, Analytical and Bioanalytical Chemistry.

[15]  N. Spooner,et al.  Investigation of the effect of blood hematocrit and lipid content on the blood volume deposited by a disposable dried blood spot collection device , 2018, Journal of pharmaceutical and biomedical analysis.

[16]  B. Poindexter,et al.  Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates , 2017, Therapeutic drug monitoring.

[17]  G. Tripodi,et al.  Volumetric adsorptive microsampling‐liquid chromatography tandem mass spectrometry assay for the simultaneous quantification of four antibiotics in human blood: Method development, validation and comparison with dried blood spot , 2017, Journal of pharmaceutical and biomedical analysis.

[18]  Kathrin Foerster,et al.  Clinical feasibility of dried blood spots: Analytics, validation, and applications. , 2016, Journal of pharmaceutical and biomedical analysis.

[19]  D. Tonoli,et al.  The use of mass spectrometry to analyze dried blood spots. , 2016, Mass spectrometry reviews.

[20]  B. Poindexter,et al.  Developmental Pharmacokinetics of Piperacillin and Tazobactam Using Plasma and Dried Blood Spots from Infants , 2014, Antimicrobial Agents and Chemotherapy.

[21]  P. Timmerman,et al.  Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium. , 2013, Bioanalysis.

[22]  K. Boussery,et al.  Development and validation of a fast and uniform approach to quantify β-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-electrospray-tandem mass spectrometry. , 2013, Talanta.

[23]  G. la Marca,et al.  Development of an UPLC-MS/MS method for the determination of antibiotic ertapenem on dried blood spots. , 2012, Journal of pharmaceutical and biomedical analysis.

[24]  P. Timmerman,et al.  EBF recommendation on the validation of bioanalytical methods for dried blood spots. , 2011, Bioanalysis.

[25]  J. McElnay,et al.  Dried blood spot assay for estimation of metronidazole concentrations in rats and its application in single animal drug pharmacokinetic study. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[26]  J. Alffenaar,et al.  Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[27]  M. Danhof,et al.  The role of population PK–PD modelling in paediatric clinical research , 2010, European Journal of Clinical Pharmacology.

[28]  J. McElnay,et al.  Development and validation of a dried blood spot–HPLC assay for the determination of metronidazole in neonatal whole blood samples , 2010, Analytical and bioanalytical chemistry.

[29]  A. Marsot Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children? , 2020, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[30]  G. Carlucci,et al.  Development of a dried blood spot HPLC-PDA method for the analysis of linezolid and ciprofloxacin in hospital-acquired pneumonia patients. , 2017, Drug testing and analysis.

[31]  E. Woolf,et al.  A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit. , 2015, Bioanalysis.